The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
 
Daria Louise Gaut
No Relationships to Disclose
 
Bradley Callas
Employment - Abbvie (I)
 
Lloyd Earl Damon
Honoraria - Acceleron Pharma (I); Actelion (I); Aerovate (I); BIAL (I); Boston Scientific (I); Janssen (I); United Therapeutics (I)
Consulting or Advisory Role - Actelion (I); Altavant (I); Atara Biotherapeutics (I); Janssen (I); Liquidia Technologies (I); Natera (I); NXT Health Strategies (I); Pulnovo Medical (I); Tectonic Therapeutic (I); Trio Health (I); United Therapeutics (I); United Therapeutics (I)
Speakers' Bureau - Pulmonary Hypertension Association (I)
Research Funding - Agios; Astellas Pharma; Jazz Pharmaceuticals; Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Mc Graw Hill Education - chapter in current Medical Diagnosis & Treatment
 
Brian Andrew Jonas
Consulting or Advisory Role - Abbvie; BMS; Daiichi Sankyo; Genentech; Gilead Sciences; GlycoMimetics; Kymera; Pfizer; Rigel; Servier
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); BMS (Inst); Celgene (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Sigma-Tau (Inst); Treadwell Therapeutics (Inst)
Other Relationship - Gilead Sciences; GlycoMimetics
 
Deepa Jeyakumar
Research Funding - Jazz Pharmaceuticals; Pfizer
 
Catherine Borror
No Relationships to Disclose
 
Stephanie Osorio
Travel, Accommodations, Expenses - Caribou Biosciences
 
Teresa Ta
No Relationships to Disclose
 
Sunmin Park
No Relationships to Disclose
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; AVM Biotechnology; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Matthew Joseph Wieduwilt
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Gilead Sciences; SERVIER
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Gilead Sciences; Pfizer; SERVIER
Research Funding - NCI (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
Other Relationship - Sorrento Therapeutics
 
Caspian Oliai
Research Funding - Arog; Jazz Pharmaceuticals; Novartis; Orca Bio; Pfizer